Clinical antihypertensive efficacy and safety of Iran plants: a systematic review

Message:
Article Type:
Research/Original Article (دارای رتبه معتبر)
Abstract:
Background

Antihypertensive plants are one of the means of hypertension control.

Objective

To examine the clinical antihypertensive efficacy and safety of the plants found in Iran.

Methods

PUBMED, MEDLINE, SCOPUS, EMBASE, SCIENCEDIRECT, PROQUEST, OVID, EBSCO, GOOGLE, and GOOGLE SCHOLAR were searched. The PRISMA guideline was observed. The search terms were Iran, Iranian, plant, herb, antihypertensive, hypertension and randomized controlled trial (RCT). English-language articles published until the end of 2022 were included. In-vitro and animal studies, editorials, and reviews were excluded. The methodological quality of the RCTs was evaluated using the JADAD scale.

Results

Two hundred and eight studies were found. Only 74 of them were eligible. For Berberis vulgaris (5 studies), Nigella sativa (10 studies), Allium sativum (12 studies), Hibiscus sabdariffa (11 studies), Beta vulgaris L (15 studies), Solanum lycopersicum (5 studies), Cinnamomum verum (9 studies), Rhus coriaria (1 study), Phyllanthus emblica (1 study), Olea europaea (4 studies), and Vaccinium arctostaphylos (3 studies) were found. Most RCTs had high methodological quality and reported efficacy and no side effects.

Conclusion

While most trials demonstrate antihypertensive efficacy and safety, there are more evidence regarding Hibiscus sabdariffa, Olea europaea, Vaccinium arctostaphylos and Allium sativum versus the other plants.

Language:
English
Published:
Journal of Medicinal Plants, Volume:22 Issue: 85, Mar 2023
Pages:
1 to 24
magiran.com/p2578836  
دانلود و مطالعه متن این مقاله با یکی از روشهای زیر امکان پذیر است:
اشتراک شخصی
با عضویت و پرداخت آنلاین حق اشتراک یک‌ساله به مبلغ 1,390,000ريال می‌توانید 70 عنوان مطلب دانلود کنید!
اشتراک سازمانی
به کتابخانه دانشگاه یا محل کار خود پیشنهاد کنید تا اشتراک سازمانی این پایگاه را برای دسترسی نامحدود همه کاربران به متن مطالب تهیه نمایند!
توجه!
  • حق عضویت دریافتی صرف حمایت از نشریات عضو و نگهداری، تکمیل و توسعه مگیران می‌شود.
  • پرداخت حق اشتراک و دانلود مقالات اجازه بازنشر آن در سایر رسانه‌های چاپی و دیجیتال را به کاربر نمی‌دهد.
In order to view content subscription is required

Personal subscription
Subscribe magiran.com for 70 € euros via PayPal and download 70 articles during a year.
Organization subscription
Please contact us to subscribe your university or library for unlimited access!